Article

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium.
BMC Genomics (Impact Factor: 3.99). 02/2008; 9(1):239. DOI: 10.1186/1471-2164-9-239
Source: PubMed

ABSTRACT

Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30-40% of ER+BC will relapse despite tamoxifen treatment. New prognostic biomarkers and further biological understanding of tamoxifen resistance are required. We used gene expression profiling to develop an outcome-based predictor using a training set of 255 ER+ BC samples from women treated with adjuvant tamoxifen monotherapy. We used clusters of highly correlated genes to develop our predictor to facilitate both signature stability and biological interpretation. Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings.
We developed a gene classifier consisting of 181 genes belonging to 13 biological clusters. In the independent set of adjuvantly-treated samples, it was able to define two distinct prognostic groups (HR 2.01 95%CI: 1.29-3.13; p = 0.002). Six of the 13 gene clusters represented pathways involved in cell cycle and proliferation. In 112 metastatic breast cancer patients treated with tamoxifen, one of the classifier components suggesting a cellular inflammatory mechanism was significantly predictive of response.
We have developed a gene classifier that can predict clinical outcome in tamoxifen-treated ER+ BC patients. Whilst our study emphasizes the important role of proliferation genes in prognosis, our approach proposes other genes and pathways that may elucidate further mechanisms that influence clinical outcome and prediction of response to tamoxifen.

Download full-text

Full-text

Available from: Els M J J Berns
  • Source
    • "The six-miRNA-signature score was then applied onto the z-scores to dichotomize patients into risk groups (High vs. Low). Six other breast cancer datasets (n = 1056)293031323334were utilized for assessment of RhoA mRNA expression in relation to DMFS. These datasets were selected for their use of Affymetrix mRNA profiling platforms with annotated DMFS outcome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A common and aggressive subtype of soft-tissue sarcoma, undifferentiated pleomorphic sarcoma (UPS) was examined to determine the role of micro-RNAs (miRNAs) in modulating distant metastasis. Following histopathologic review, 110 fresh frozen clinically annotated UPS samples were divided into two independent cohorts for Training (42 patients), and Validation (68 patients) analyses. Global miRNA profiling on the Training Set and functional analysis in vitro suggested that miRNA-138 and its downstream RHO-ROCK cell adhesion pathway was a convergent target of miRNAs associated with the development of metastasis. A six-miRNA signature set prognostic of distant metastasis-free survival (DMFS) was developed from Training Set miRNA expression values. Using the six-miRNA signature, patients were successfully categorized into high- and low-risk groups for DMFS in an independent Validation Set, with a hazard ratio (HR) of 2.25 (p = 0.048). After adjusting for other known prognostic variables such as age, gender, tumor grade, size, depth, and treatment with radiotherapy, the six-miRNA signature retained prognostic value with a HR of 3.46 (p < 0.001). A prognostic miRNA biomarker for clinical validation was thus identified along with a functional pathway that modulates UPS metastatic phenotype.
    Preview · Article · Apr 2015 · Oncotarget
  • Source
    • "In this study, six hundred and ninty nine retrospective datasets of early stage (Stage I and II) Estrogen Positive (EC+) Breast Cancer of women treated and not treated with tamoxifenmonotherapy diagnosed between 1980 to1995 from GEO Database [11] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The twenty first century sees the tremendous advancement of computer and machine technologies that are able to produce ginormous amout of data. Current software architecture, management and analysis approaches are unable to cope with the flood of data. The challenge of understanding large and complex data includes issues such as clutter, performance, information loss and limited cognition. Medical field involves analyzing the body system which includes many different scientists and medical professionals. The datasets are a hybrid of many different medical areas databases to understand and answer the many questions of the human body. This paper explores the capability of interactive star coordinate visualization technique to identify clusters correlation between selected attributes using interactive star coordinate for multi-dimensional datasets An interactive Star coordinates is designed consists of four stages that includes Information Objects Transformation; Dimension Mapping; Interactive Features design and Coloring. Finally the performance of the interactive star coordinates is compared to histograms of the data of interest. Interactive star coordinate is found as a promising method of visualizing information clusters pattern which provides one of the means for fast decision making.
    Full-text · Article · Dec 2014 · Procedia Computer Science
  • Source
    • "The data revealed three gene signatures consisting of a total of 14 genes (AKT1, BCAR3, BCL2, CDKN1A, CGA, EGFR, ESR1, IGF1R, NAT1, NCOA1, NRG1, PRKCD, PRKCE and TFF1). The strongest prediction of outcome (75% accuracy) was obtained with a 2-gene combination of BCL2 and CDKN1A and confirmed by independent examination of 4 previouslyreported microarray datasets of tamoxifen-treated patient samples in the adjuvant setting (n ¼ 503)(Chanrion et al., 2008; Loi et al., 2008; Ma et al., 2004; Zhang et al., 2009). The predictive value was further validated by comparing the ability of the genes to predict recurrence in an additional, previouslypublished , cohort (Loi et al., 2007) consisting of both adjuvant tamoxifen-treated and untreated patients (Lyng et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To identify molecular markers indicative of response to tamoxifen and easily implemented in the in the routine setting, we recently reported three gene signatures that could stratify post-menopausal tamoxifen-treated, estrogen receptor-positive (ER+) patients according to outcome in the adjuvant setting. Here, we evaluated the predictive potential of the total of 14 genes included in the 3 gene signatures using 2 hormone-naïve Dutch ER+ cohorts of a total of 285 recurrent breast cancer patients treated with first-line tamoxifen. mRNA levels were measured by reverse transcriptase quantitative PCR (RT-qPCR) and the length of progression-free survival (PFS) was used as the primary endpoint. A Mann-Whitney U test was used to select for differentially expressed genes between tumors of patients who showed or did not show progressive disease within 6 months after start of tamoxifen treatment. Cox univariate and multivariate regression analysis for PFS were used to further assess their (independent) predictive potential. Five (BCAR3, BCL2, ESR1, IGF1R, and NCOA1) of the 14 genes analyzed showed significantly higher mRNA levels in tumors of patients who showed no disease progression within 6 months. Only BCAR3, BCL2 and NAT1 were significantly associated with a favorable PFS in multivariate analysis that included the traditional predictive factors: age, dominant relapse site, disease-free interval, ER and progesterone receptor (PGR), and adjuvant chemotherapy. This study shows that BCAR3, BCL2 and NAT1 in particular exhibit predictive promise regarding the efficacy of tamoxifen treatment in recurrent disease, in addition to the previously shown favorable outcome in the adjuvant setting.
    Full-text · Article · Dec 2014 · Molecular Oncology
Show more